Animal & Veterinary

Arthritis Drug for Horses and Dogs Scheduled to Return to Market

August 5, 2013

FDA’s Center for Veterinary Medicine (CVM) has recently received phone calls and emails from consumers who were unable to obtain Adequan IM and IA (polysulfated glycosaminoglycan), and Adequan Canine, an FDA-approved drug for the control of signs associated with non-infectious degenerative and/or traumatic lameness in horses and canines.

In response to these consumer inquiries, FDA contacted Luitpold Pharmaceuticals, Inc., the manufacturer of Adequan, and learned that the product will be available again beginning later this month (August, 2013).

For more information about this unanticipated shortage, consumers can visit the following link: www.adequan.comdisclaimer icon, the company’s webpage dedicated to Adequan. Or, call Luitpold Animal Health Customer Service Department at 1-800-458-0163.
 

Contact FDA

240-276-9300
240-276-9115 FAX
Issued by: FDA, Center for Veterinary Medicine

Communications Staff, HFV-12

7519 Standish Place

Rockville, MD 20855

Page Last Updated: 08/05/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.